<div id="readability-page-1"><div>(TheNewswire)<ul><ul></ul></ul> Vancouver, British Columbia – April 1, 2026 – TheNewswire - MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF) (the “Company” or “MindBio”), a biotechnology company that is commercialising prediction technologies for drug and alcohol intoxication detection using speech analytics and artificial intelligence, is pleased to announce that it has closed its previously announced upsized non-brokered private placement (the “Offering”) for gross proceeds of $1,437,828.87 Pursuant to the Offering, the Company issued an aggregate of 2,396,381 units (each, a “Unit”) at a price of $0.60 per Unit for gross proceeds of $1,437,828.87. Each Unit consists of one common share of the Company (each, a “Share”) and one Share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder to acquire an additional Share at a price of $0.80 for a period of thirty-six months following closing of the Offering, subject to accelerated expiry in the event the closing price of the Shares on the Canadian Securities Exchange (the “CSE”) exceeds $1.00 for ten consecutive trading days. The Company intends to use the net proceeds from the Offering to accelerate the development and deployment of a proprietary hardware and edge technology which will enable the remote and scalable use of MindBio’s intoxication detection solution at mining sites, for recruitment of specialised personnel and for general working capital purposes. In connection with completion of the Offering, the Company paid aggregate cash fees of $70,183.97 and issued an aggregate of 116,973 non-transferable Share purchase warrants (each, a “Finder Warrant”) to eligible third-parties who introduced subscribers to the Offering. Each Finder Warrant entitles the holder thereof to acquire one Share at a price of $0.80 for a period of thirty-six months after the date of issue, subject to accelerated expiry in the event the closing price of the Shares on the CSE exceeds $1.00 for ten consecutive trading days. All securities issued in connection with the Offering are subject to restrictions on resale for a period of four-months-and-one-day in accordance with applicable securities laws. The Offering remains subject to final regulatory approvals. Promotional and Communications Engagements MindBio also announces that it has entered into agreements with two arm’s length service providers to provide promotional, communications, marketing and advertising services to the Company. The Company has engaged Stockouse Publishing Ltd dba The Market Link (“The Market Link”) pursuant to an advertising campaign agreement and Investor Brand Network (“IBN”) pursuant to a syndicated communications agreement. The purpose of these engagements is to increase public awareness of the Company and broaden dissemination of the Company’s news and information. Neither engagement includes market making services, and no securities of the Company will be issued as compensation in connection with either engagement. The Company confirms that both The Market Link and IBN are arm’s length parties to the Company. To the knowledge of the Company, neither The Market Link nor IBN has any direct or indirect interest in the Company or its securities. The Market Link engagement commenced on March 24, 2026 and will continue until March 24, 2027. Under the engagement, an assigned account manager will support campaign planning, execution and optimization throughout the program term. Services include access to issuer advertising inventory across listed platforms, strategic support from an account manager, campaign execution, and performance reporting. The promotional activity will occur through The Market Link’s selected publishers and investor platforms. The Market Link will receive cash compensation of $36,750 payable upfront upon closing of the Company’s private placement. No stock options or other securities-based compensation will be granted in connection with the engagement. The Market Link contact details are as follows: Stockouse Publishing Ltd dba The Market Link 1130 - 1055 West Hastings St. Vancouver, BC V6E 2E9 Email: info@themarketlink.com Telephone: 1-778-588-7012The IBN engagement commenced on March 25, 2026 and willcontinue until March 25, 2027. Under the engagement, IBN will providean investor awareness and media exposure program intended to increasethe Company’s market visibility and broaden investor reach. Servicesinclude ongoing content distribution such as articles, newsletterfeatures, press release amplification and recap coverage acrossIBN’s media, syndication and social channels. The engagement alsoincludes promotional support through interviews, social mediarelations, and access to IBN’s partner network and consultingexperience. The promotional activity will occur through InvestorWire,InvestorNewsBreaks, IBN newsletters, IBN’s social media network,podcast directories including Apple Podcasts, Spotify and iHeartRadio,and broader syndication channels. IBN will receive cash compensationof $34,847.50 per quarter for a 12-month term, for aggregatecompensation of $139,390. No stock options or other securities-basedcompensation will be granted in connection with the engagement.The IBN contact details are as follows:Investor Brand Network1108 Lavaca Street, Suite 110-IBNAustin, TX 78701Contact : Dutch DeWaardEmail: Dutch@IBN.fm General Office Telephone: (512) 354-7000Contact Telephone: 480-734-5834For further information, please contact:Justin Hanka, Chief ExecutiveOfficer+61 433140886justin@mindbiotherapeutics.comwww.mindbiotherapeutics.comAbout MindBio TherapeuticsCorp.MindBio is a biotechnologycompany that is commercialising AI prediction technologies for drugand alcohol intoxication detection via voice analysis. The AIprediction model uses over 50 million data points to predict alcoholintoxication with remarkable accuracy, just by using the human voice.The Company is now collecting data that will allow its prediction toolto work on other types of intoxication for use in consumer andenterprise environments.Cautionary Note ConcerningForward-Looking Statements: The press release contains “forward-lookingstatements” within the meaning of applicable securities laws,including but not limited to, statements regarding the intended use ofproceeds from the Offering, including the development of theCompany’s enterprise platform using voice and powered by AI for usein detecting drug and alcohol intoxication, and the expected duration,scope and anticipated benefits of the Company’s engagements with TheMarket Link and Investor Brand Network. Forward-looking statements canbe identified by words such as: “anticipate,” “intend,”“plan,” “budget,” “believe,” “project,”“estimate,” “expect,” “scheduled,”“forecast,” “strategy,” “future,” “likely,” “may,”“to be,” “could,” “would,” “should,” “will” andsimilar references to future periods or the negative or comparableterminology, as well as terms usually used in the future andconditional. Forward-looking statements are based on assumptions as ofthe date they are provided. However, there can be no assurance thatsuch assumptions will reflect the actual outcome of such items orfactors. Additionally, there are known and unknown risk factorsthat could cause the Company’s actual results and financialconditions to differ materially from those indicated in theforward-looking statements. Therefore, you should not rely on any ofthese forward-looking statements. Important risk factors that couldcause actual results and financial conditions to differ materiallyfrom those indicated in the forward-looking statements, include amongothers: the failure to obtain the final regulatory approval; technicalchallenges in the development or deployment of its enterpriseplatform; general economic, market and businessconditions in Canada and Australia; market volatility; and unforeseendelays in timelines for any of the transactions or events described inthis press release. All forward-looking information is qualified inits entirety by this cautionary statement. The Company disclaims any obligation to revise orupdate any such forward-looking statement or to publicly announce theresult of any revisions to any of the forward-looking informationcontained herein to reflect future results, events or developments,except as required by law.Neither the Canadian Securities Exchange nor itsRegulation Service Provider (as that term is defined in the policiesof the Canadian Securities Exchange) accepts responsibility for theadequacy or accuracy of this release.Copyright (c) 2026 TheNewswire - All rights reserved.</div></div>

NBSE.ESC

BTMD

SBIO

MindBio Therapeutics Corp. has successfully closed a private placement, raising $1,437,828.87 by issuing 2,396,381 units at $0.60 each. The funds will be used to enhance the development of its intoxication detection technology. Additionally, the company has engaged two service providers for promotional and marketing services to increase public awareness and investor reach. The engagements include cash compensation and will run for one year. All securities issued are subject to resale restrictions for four months and are pending final regulatory approvals.

MindBio Announces Closing of Private Placement